UPDATE: Piper Jaffray Cuts PT to $15 on Achillion Pharmaceuticals on Equity Offering Dilution

UPDATE: Piper Jaffray Cuts PT to $15 on Achillion Pharmaceuticals on Equity Offering Dilution

By: Latest Articles from Benzinga.com

Posted on March 04, 2013 at 12:55 PM EST

Piper Jaffray maintained Achillion Pharmaceuticals (NASDAQ: ACHN ) with an Overweight rating and lowered the price target from $16.00 to $15.00. Piper Jaffray said, "Achillion now holds proforma cash of $211 million following a recent 16.9 million share offering. We are buyers of ACHN shares ahead of SVR-4 data from

Related Stocks:

Achillion Pharmaceuticals, Inc.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates